Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Azacitidine (AZA) and venetoclax (VEN) combination for the treatment of immune mediate inflammatory diseases (IMID) associated with myeloid neoplasms (MN)

Armelle Otiniano, Vincent Jachiet, Jerome Hadjadj, Mael Heiblig, Pierre LOZAC H, Mathieu Wemeau, Maxime Battistella, Mirabelle Ruyer Thompson, Eve Zakine, Urbain Tauveron-Jalenques, Marc Ruivard, Benoit De Renzis, Pierre Fenaux, Olivier Fain, Lin-Pierre Zhao, Arsene Mekinian

Blood (2025) 146 (Supplement 1): 5630.

https://doi.org/10.1182/blood-2025-5630

Published: 2025

Journal Articles

Clinical outcome of patients with TP53 AML treated with non-intensive vidaza-venetoclax chemotherapy : Venaura retrospective regional multicenter study.

Chloe Cote, Mael Heiblig, Urbain Tauveron-Jalenques, Martin Carre, Amine Belhabri, Gaspar Aspas Requena, Sylvain Lamure, Ugo Thévenet, Clemence Santana, Adrien Contejean, Jerome Cornillon, Elisabeth Daguenet, Pascale Flandrin-Gresta, Emmanuelle Tavernier

Blood (2025) 146 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2025-3442

Published: 2025

Journal Articles

Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study

Blood (2025) 146 (Supplement 1): 3398.

https://doi.org/10.1182/blood-2025-3398

Published: 2025

Journal Articles

Outcomes of older or unfit AML patients admitted to intensive care unit in the venetoclax era

Blood (2025) 146 (Supplement 1): 5225.

https://doi.org/10.1182/blood-2025-5225

Published: 2025

Journal Articles

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Blood (2025) 146 (Supplement 1): 453.

https://doi.org/10.1182/blood-2025-453

Published: 2025

Journal Articles

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Blood (2025) 146 (Supplement 1): 5278.

https://doi.org/10.1182/blood-2025-5278

Published: 2025

Journal Articles

Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group

Adrien Contejean, Pierre Chauvelot, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Martin Carre, Emmanuelle Tavernier, Jérôme Cornillon, Clémence Santana, Clément Rocher, Sylvain Lamure, Natacha Mauz, Ugo Thévenet, Boullanger Fow Heng Nadine, Gian Matteo Pica, Arthur Dony, Amine Belhabri, Mauricette Michallet, Zofia Gross, Mael Heiblig

Blood (2024) 144 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2024-207605

Published: 2024

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group

Urbain Tauveron-Jalenques, Zofia Gross, Martin Carre, Emmanuelle Tavernier, Jérôme Cornillon, Adrien Contejean, Clemence Santana, Clément Rocher, Sylvain Lamure, Natacha Mauz, Ugo Thévenet, Boullanger Fow Heng Nadine, Pica Gian-Matteo, Dony Arthur, Amine Belhabri, Mauricette Michallet, Pedro Chorao, Mael Heiblig, Gaspar Aspas Requena

Blood (2024) 144 (Supplement 1): 3564.

https://doi.org/10.1182/blood-2024-208577

Published: 2024

Journal Articles

Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group

Mael Heiblig, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Jérome Cornillon, Martin Carre, Mathieu Meunier, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Zofia Gross

Blood (2024) 144 (Supplement 1): 846.

https://doi.org/10.1182/blood-2024-207764

Published: 2024

Journal Articles

Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Martin Carre, Mathieu Meunier, Zofia Gross, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Jérome Cornillon, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Mael Heiblig

Blood (2024) 144 (Supplement 1): 4335.

https://doi.org/10.1182/blood-2024-208817

Published: 2024

Journal Articles

Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group

Emmanuelle Tavernier, Jérôme Cornillon, Zofia Gross, Gaspar Aspas Requena, Urbain Tauveron-Jalenques, Martin Carré, Mathieu Meunier, Ugo Thévenet, Boullanger Fow Heng Nadine, Clémence Santana, Clément Rocher, Sylvain Lamure, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Gian Matteo Pica, Arthur Dony, Mael Heiblig

Blood (2024) 144 (Supplement 1): 1518.

https://doi.org/10.1182/blood-2024-203496

Published: 2024

Journal Articles

Efficacy of Chemo-Free Combination Therapy with BRAF Inhibitor and Rituximab in Classic Hairy Cell Leukemia: Insights from the French Experience

Luca Inchiappa, Lise Willems, Jérôme Paillassa, Charles Herbaux, Cecile Tomowiak, Anne Lok, Diane Lara, Bijou Fontanet, Urbain Tauveron-Jalenques, Antoine Ittel, Adrien Caillet, Norbert Vey, Xavier Troussard

Blood (2023) 142 (Supplement 1): 6170.

https://doi.org/10.1182/blood-2023-186971

Published: 2023

Journal Articles

Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group

Zofia Gross, Urbain Tauveron-Jalenques, Gaspar Aspas Requena, Martin Carre, Mathieu Meunier, Emmanuelle Tavernier, Jérôme Cornillon, Amine Belhabri, Mauricette Michallet, Adrien Contejean, Natacha Mauz, Boullanger FOW HENG Nadine, Daciana Claudia Antal, Gian Matteo Pica, Dony Arthur, Clémence Santana, Clement Rocher, Mael Heiblig

Blood (2023) 142 (Supplement 1): 590.

https://doi.org/10.1182/blood-2023-187331

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Azacitidine (AZA) and venetoclax (VEN) combination for the treatment of immune mediate inflammatory diseases (IMID) associated with myeloid neoplasms (MN)

Clinical outcome of patients with TP53 AML treated with non-intensive vidaza-venetoclax chemotherapy : Venaura retrospective regional multicenter study.

Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study

Outcomes of older or unfit AML patients admitted to intensive care unit in the venetoclax era

Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: a multinational retrospective cohort study

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Infectious Complications Among Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia: A Multicentric Real-Life Analysis of the French Auraml Group

Allogeneic Hematopoietic Cell Transplantation in Newly Diagnosed and Relapse/Refractory AML Patients Post Venetoclax-Azacitidine Treatment: A Multicenter Real-Life Analysis By the French Auraml Group

Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group

Azacytidine and Venetoclax As a Salvage Therapy in Measurable Residual Disease (MRD) Relapse Post Intensive Chemotherapy or Allogenic Stem Cell Transplantation in Acute Myeloid Leukemia Patients : A Multicentric Study from French Auraml Group

Azacitidine and Venetoclax As a Salvage Therapy for Relapse after Allogeneic Transplantation for Acute Myeloid Leukemia : A Multicentric Study from French Auraml Group

Efficacy of Chemo-Free Combination Therapy with BRAF Inhibitor and Rituximab in Classic Hairy Cell Leukemia: Insights from the French Experience

Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only